We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Point-Of-Care HbA1c Analyzer Enhanced

By LabMedica International staff writers
Posted on 29 Mar 2011
A point-of-care (POC) immunoassay analyzer for diabetes management provides enhanced operator management and connectivity capabilities to meet the growing demands in POC testing for improved compliance management and data capture into patient records.

The DCA Vantage Analyzer ensures that all analyzers are running the same quality control regimen required by their institution and that only authorized operators are running the devices according to their specified access level.

The operator management capability has been expanded to support up to 1,000 operators, each with their unique access level as defined by their supervisor. Another enhancement to the analyzer is the ability to display, print, and transmit the HbA1c reference ranges with the patient results, aiding in improved results interpretation.

POC managers are demanding better connectivity between their POC analyzers and the associated healthcare organization so that test results can be automatically transmitted to the laboratory and hospital information systems, and eventually to the patient's electronic medical record.

Siemens Healthcare Diagnostics (Erlangen, Germany) launched the DCA Vantage Analyzer with Version 3.0 software. It has the capacity to manage a larger number of operators while providing the required security access modes to prevent unauthorized use. In addition, the analyzer is one of the first hemoglobin A1c (HbA1c) POC analyzers in the industry to include the POCT1-A2 communication protocol. Use of this standard interface simplifies the connection to POC data management systems, enabling results to be automatically transmitted to the patient electronic medical record.

"We are focused on providing our customers with a trusted, clinically proven, point-of-care analyzer to better manage diabetes patients at the time of visit," said Dr. David Stein, CEO, POC business unit, Siemens Healthcare Diagnostics. "At the same time, we are continually looking at ways to enhance our products to meet the changing needs of our customers. These newly added features are important to point-of-care managers who are responsible for tests conducted at remote sites with multiple operators and devices in order to drive testing compliance."

Related Links:

Siemens Healthcare Diagnostics



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics

Latest Clinical Chem. News

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
29 Mar 2011  |   Clinical Chem.

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
29 Mar 2011  |   Clinical Chem.

Low-Cost Portable Screening Test to Transform Kidney Disease Detection
29 Mar 2011  |   Clinical Chem.